Glaucoma Therapeutics Market Industry Growth 2026: Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Aristo Pharmaceuticals Pvt. Ltd., Santen P

For instance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1675

Furthermore, in 2010, over 8 million people were bilaterally blind due to glaucoma, which is expected to increase to over 11 million by 2020. The significant risk of developing glaucoma increases with geriatric population, increased intraocular pressure, positive family history for glaucoma, and ethnicity. According to the American Academy of Ophthalmology (AAO), 2016: the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040.

Increasing number of patients with glaucoma and increasing incidences of blindness are expected to be the major driving factor for growth of the global glaucoma therapeutics market. According to the International Agency for the Prevention of Blindness, 2010 data findings, it is estimated that by 2020, around 80 million people will suffer from glaucoma, with an increase of about 20 million form 2010.

For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%).

Some of the key players operating in the glaucoma therapeutics market include Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. Key players in the market are focusing on organic growth strategies in order to gain maximum market share and retain leading position in the market.

Get Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1675

Glaucoma Therapeutics Market Taxonomy:

By Disease Type

Primary Open Angle Glaucoma (POAG)
Primary Angle Closure Glaucoma (PACG)
By Drug Class:

Alpha adrenergic Agonist
Beta Blockers
Prostaglandin Analogs
Carbonic Anhydrase Inhibitor
Cholinergic
Combined Medication
Fixed-dose Combinations
By End Users:

Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Others
By Geography:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.